Literature DB >> 10807782

Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness.

H J Koenen1, I Joosten.   

Abstract

The generation of immunoregulatory T cells that block the B7(CD86/CD80)-CD28 and/or CD40-CD154 costimulatory pathways has great potential for the induction of long-term transplantation tolerance. In a human polyclonal in vitro model, combined monoclonal antibody (mAb) blocking of the costimulatory ligands CD40 and CD86 lead to allospecific T-cell anergy that cannot be reversed by antigenic rechallenge in the presence of IL-2. Although antigenic restimulation with IL-2 restored the proliferative response, subsequent antigenic restimulation of the restored anergic cells in a tertiary mixed lymphocyte culture still resulted in nonresponsiveness. Importantly, these anergic T cells suppress the response of naive alloreactive T cells in an antigen-specific way via linked recognition. Suppression may partially depend on local IL-10 production, while transforming growth factor-beta (TGF-beta) did not play a role. Irrespective of the monoclonal antibody combination used, blast formation occurred in a subset of CD4(+) cells. These cells were characterized by a sustained CD45RA expression, an increased T-cell receptor density, and a lower level of CD4 expression. A reduced number of CD45RO(+)/CD8(+) T cells was observed whenever anti-CD86 was combined with anti-CD40, which was reflected by an even more attenuated cytotoxic T-cell function. This indicates the importance of CD40-CD154 in the generation of cytotoxic T cells in this transplantation model. We hypothesize that in our model, anergy is induced in the CD4(+) T-cell subset, whereby CD8(+) cytotoxic effector function is impaired by the lack of both CD40-CD154 signaling and cytokine-mediated help. This costimulatory ligand-directed mAb approach might well be used for the ex vivo generation of antigen-specific immunoregulatory T cells applicable in adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807782

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Expansion of allospecific regulatory T cells after anergized, mismatched bone marrow transplantation.

Authors:  Jeffrey K Davies; Lee M Nadler; Eva C Guinan
Journal:  Sci Transl Med       Date:  2009-10-07       Impact factor: 17.956

Review 2.  Costimulatory blockade with monoclonal antibodies to induce alloanergy in donor lymphocytes.

Authors:  Jeffrey K Davies
Journal:  Int J Hematol       Date:  2011-04-08       Impact factor: 2.490

3.  Phenotypic characterization of human decidual macrophages.

Authors:  J Heikkinen; M Möttönen; J Komi; A Alanen; O Lassila
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

4.  Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity.

Authors:  Jeffrey K Davies; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

5.  Granulocyte-colony stimulating factor drives the in vitro differentiation of human dendritic cells that induce anergy in naïve T cells.

Authors:  Maura Rossetti; Silvia Gregori; Maria Grazia Roncarolo
Journal:  Eur J Immunol       Date:  2010-10-19       Impact factor: 5.532

6.  Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies.

Authors:  Jeff K Davies; John G Gribben; Lisa L Brennan; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Blood       Date:  2008-07-10       Impact factor: 22.113

Review 7.  Manipulation of Regulatory Dendritic Cells for Induction Transplantation Tolerance.

Authors:  Weitao Que; Wen-Zhi Guo; Xiao-Kang Li
Journal:  Front Immunol       Date:  2020-10-14       Impact factor: 7.561

8.  Dimethyl fumarate as a first- vs second-line therapy in MS: Focus on B cells.

Authors:  Elsebeth Staun-Ram; Eiman Najjar; Anat Volkowich; Ariel Miller
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-10-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.